O	0	10	Randomized
O	11	18	placebo
O	18	19	-
O	19	29	controlled
O	30	35	pilot
O	36	41	trial
O	42	44	of
B-intervention	45	50	omega
I-intervention	51	52	3
I-intervention	53	58	fatty
I-intervention	59	64	acids
O	65	68	for
O	69	79	prevention
O	80	82	of
B-condition	83	92	aromatase
I-condition	93	102	inhibitor
I-condition	102	103	-
I-condition	103	110	induced
I-condition	111	126	musculoskeletal
I-condition	127	131	pain
O	131	132	.

O	133	142	Aromatase
O	143	152	inhibitor
O	153	154	(
O	154	156	AI
O	156	157	)
O	157	158	-
O	158	165	induced
O	166	171	joint
O	172	180	symptoms
O	181	191	negatively
O	192	198	impact
O	199	203	drug
O	204	213	adherence
O	214	217	and
O	218	225	quality
O	226	228	of
O	229	233	life
O	234	236	in
O	237	243	breast
O	244	250	cancer
O	251	260	survivors
O	260	261	.

O	262	272	Mechanisms
O	273	283	underlying
O	284	292	symptoms
O	293	296	may
O	297	304	include
O	305	317	inflammation
O	317	318	.

O	319	321	It
O	322	324	is
O	325	337	hypothesized
O	338	342	that
O	343	344	n
O	345	346	-
O	347	348	3
O	349	364	polyunsaturated
O	365	370	fatty
O	371	376	acids
O	377	378	(
O	378	383	PUFAs
O	383	384	)
O	385	389	have
O	390	394	anti
O	394	395	-
O	395	407	inflammatory
O	408	418	properties
O	419	422	and
O	423	426	may
O	427	433	reduce
O	434	442	symptoms
O	442	443	.

O	444	446	We
O	447	456	conducted
O	457	458	a
O	459	469	randomized
O	469	470	,
O	471	477	double
O	477	478	-
O	478	483	blind
O	483	484	,
O	485	492	placebo
O	492	493	-
O	493	503	controlled
O	504	509	study
O	510	519	comparing
O	520	521	4
O	521	522	.
O	522	523	3
O	524	525	g
O	525	526	/
O	526	529	day
O	530	531	n
O	532	533	-
O	534	535	3
O	536	540	PUFA
O	541	552	supplements
O	553	555	vs
B-control	556	563	placebo
O	564	567	for
O	568	570	24
O	571	576	weeks
O	577	579	in
B-eligibility	580	594	postmenopausal
I-eligibility	595	601	breast
I-eligibility	602	608	cancer
I-eligibility	609	617	patients
I-eligibility	618	626	starting
I-eligibility	627	635	adjuvant
I-eligibility	636	639	AIs
O	639	640	.

O	641	648	Primary
O	649	658	endpoints
O	659	663	were
B-outcome-Measure	664	673	adherence
I-outcome-Measure	674	677	and
I-outcome-Measure	678	690	tolerability
O	690	691	;
O	692	701	secondary
O	702	710	outcomes
O	711	719	included
B-outcome-Measure	720	732	inflammatory
I-outcome-Measure	733	742	cytokines
I-outcome-Measure	743	746	and
I-outcome-Measure	747	755	symptoms
O	756	764	assessed
O	765	767	by
O	768	771	the
O	772	777	Brief
O	778	782	Pain
O	783	792	Inventory
O	793	798	short
O	799	803	form
O	804	805	(
O	805	808	BPI
O	808	809	-
O	809	811	SF
O	811	812	)
O	813	816	and
O	817	827	Functional
O	828	838	Assessment
O	839	841	of
O	842	848	Cancer
O	849	858	Treatment
O	858	859	-
O	859	868	Endocrine
O	869	877	Symptoms
O	878	879	(
O	879	883	FACT
O	883	884	-
O	884	886	ES
O	886	887	)
O	888	890	at
O	891	892	0
O	892	893	,
O	894	896	12
O	896	897	,
O	898	901	and
O	902	904	24
O	905	910	weeks
O	910	911	.

B-total-participants	912	917	Forty
I-total-participants	917	918	-
I-total-participants	918	922	four
O	923	928	women
O	929	933	were
O	934	944	randomized
O	944	945	,
O	946	948	of
O	949	954	which
B-total-participants	955	957	35
O	958	967	completed
O	968	971	the
O	972	977	study
O	977	978	.

B-outcome	979	988	Adherence
O	989	992	was
O	993	994	â‰¥
O	995	997	88
O	997	998	%
O	999	1004	based
O	1005	1007	on
O	1008	1013	these
O	1014	1016	35
O	1017	1025	patients
O	1026	1030	with
O	1031	1035	pill
O	1036	1042	counts
O	1043	1045	as
O	1046	1050	well
O	1051	1053	as
O	1054	1060	change
O	1061	1063	in
O	1064	1067	red
O	1068	1073	blood
O	1074	1078	cell
O	1079	1080	(
O	1080	1083	RBC
O	1083	1084	)
O	1085	1086	n
O	1087	1088	-
O	1089	1090	3
O	1091	1096	PUFAs
O	1096	1097	.

O	1098	1104	Common
O	1105	1115	toxicities
O	1116	1124	included
B-outcome	1125	1130	grade
I-outcome	1131	1132	1
I-outcome	1133	1143	flatulence
O	1144	1145	(
B-iv-bin-percent	1145	1147	55
I-iv-bin-percent	1147	1148	%
O	1149	1151	of
O	1152	1156	both
O	1157	1163	groups
O	1163	1164	)
O	1165	1168	and
B-outcome	1169	1177	belching
O	1178	1179	(
B-iv-bin-percent	1179	1181	45
I-iv-bin-percent	1181	1182	%
O	1183	1185	of
O	1186	1187	n
O	1188	1189	-
O	1190	1191	3
O	1192	1197	group
O	1197	1198	)
O	1198	1199	.

B-outcome	1200	1204	Mean
I-outcome	1205	1209	pain
I-outcome	1210	1218	severity
I-outcome	1219	1225	scores
I-outcome	1226	1227	(
I-outcome	1227	1230	BPI
I-outcome	1230	1231	-
I-outcome	1231	1233	SF
I-outcome	1233	1234	)
O	1235	1238	did
O	1239	1242	not
O	1243	1249	change
O	1250	1263	significantly
O	1264	1266	by
O	1267	1271	time
O	1272	1274	or
O	1275	1284	treatment
O	1285	1288	arm
O	1288	1289	.

B-outcome	1290	1297	Quality
I-outcome	1298	1300	of
I-outcome	1301	1305	life
I-outcome	1305	1306	,
I-outcome	1307	1312	based
I-outcome	1313	1315	on
I-outcome	1316	1320	FACT
I-outcome	1320	1321	-
I-outcome	1321	1323	ES
I-outcome	1324	1330	scores
O	1330	1331	,
O	1332	1345	significantly
O	1346	1355	decreased
O	1356	1362	within
O	1363	1370	placebo
O	1371	1372	(
O	1372	1373	p
O	1374	1375	=
O	1376	1377	0
O	1377	1378	.
O	1378	1380	04
O	1380	1381	)
O	1381	1382	,
O	1383	1386	but
O	1387	1390	not
O	1391	1394	the
O	1395	1396	n
O	1397	1398	-
O	1399	1400	3
O	1401	1406	group
O	1407	1408	(
O	1408	1409	p
O	1410	1411	=
O	1412	1413	0
O	1413	1414	.
O	1414	1416	58
O	1416	1417	)
O	1417	1418	,
O	1419	1423	with
O	1424	1425	a
O	1426	1431	trend
O	1432	1438	toward
O	1439	1446	between
O	1446	1447	-
O	1447	1452	group
O	1453	1464	differences
O	1465	1466	(
O	1466	1467	p
O	1468	1469	=
O	1470	1471	0
O	1471	1472	.
O	1472	1474	06
O	1474	1475	)
O	1476	1478	at
O	1479	1481	12
O	1482	1487	weeks
O	1487	1488	,
O	1489	1492	but
O	1493	1495	no
O	1496	1507	significant
O	1508	1519	differences
O	1520	1522	at
O	1523	1525	24
O	1526	1531	weeks
O	1531	1532	.

B-outcome	1533	1536	RBC
I-outcome	1537	1538	n
I-outcome	1539	1540	-
I-outcome	1541	1542	3
I-outcome	1543	1549	levels
O	1550	1554	were
O	1555	1563	strongly
O	1564	1574	positively
O	1575	1585	correlated
O	1586	1590	with
O	1591	1595	FACT
O	1595	1596	-
O	1596	1598	ES
O	1599	1601	at
O	1602	1604	12
O	1605	1610	weeks
O	1610	1611	,
O	1612	1615	but
O	1616	1626	attenuated
O	1627	1629	at
O	1630	1632	24
O	1633	1638	weeks
O	1638	1639	.

O	1640	1644	High
O	1644	1645	-
O	1645	1649	dose
O	1650	1651	n
O	1652	1653	-
O	1654	1655	3
O	1656	1660	PUFA
O	1661	1676	supplementation
O	1677	1679	is
O	1680	1688	feasible
O	1689	1692	and
O	1693	1697	well
O	1698	1707	tolerated
O	1708	1712	when
O	1713	1725	administered
O	1726	1730	with
O	1731	1734	AIs
O	1734	1735	.

O	1736	1746	Additional
O	1747	1754	studies
O	1755	1758	are
O	1759	1765	needed
O	1766	1768	to
O	1769	1777	evaluate
O	1778	1786	efficacy
O	1787	1789	in
O	1790	1800	prevention
O	1801	1803	of
O	1804	1809	joint
O	1810	1818	symptoms
O	1818	1819	.
